Compare · MNKD vs NVO
MNKD vs NVO
Side-by-side comparison of MannKind Corporation (MNKD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNKD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 179.0x MNKD ($1.25B).
- Over the past year, MNKD is up 7.3% and NVO is down 21.8% - MNKD leads by 29.1 points.
- MNKD has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for MNKD).
- Company
- MannKind Corporation
- Novo Nordisk A/S
- Price
- $4.03-0.49%
- $50.31-2.25%
- Market cap
- $1.25B
- $222.81B
- 1M return
- +4.01%
- +15.47%
- 1Y return
- +7.33%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 8
- 5
- Recent ratings
- 14
- 25
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MNKD
- Chief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)
- Pres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)
- Chief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)
- Chief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)
- EVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)
- EVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)
- Director Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)
- MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S